TORONTO, Dec. 11, 2018 /CNW/ - Delivra Corp. (TSXV:
DVA - "Delivra" or the "Company") today announced the
publication of positive data from a pre-clinical study
demonstrating the safety and efficacy to treat pain directly with a
topical version of Advil™ (ibuprofen) and Celebrex™ (celecoxib).
Testing for effects on joint pain and inflammation; topical
Delivra-ibuprofen and Delivra-celecoxib formulations offer
sustained long-term pain and swelling reduction, compared to oral
equivalents. These results were published in the respected
peer-reviewed scientific journal, Journal of Pain Research, under
the title, "Penetration and efficacy of transdermal NSAIDs in a
model of acute joint inflammation". The article may be found at the
following link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239099/?report=reader
In pre-clinical testing, undertaken by an independent
third-party research organization, the Delivra-ibuprofen and
Delivra-celecoxib formulations provided sustained pain reduction.
In the study, both Delivra formulations were tested in an acute dog
model of arthritis where the formulation performed equally or
better for swelling and pain reduction compared its oral equivalent
and test controls. This exemplifies Delivra's technology, with its
multi-laminar system, is capable of gradually releasing the active
ingredient to the area of need. This transdermal, designed "slow
release" is a valuable and highly advantageous characteristic of
the topical Delivra-ibuprofen and Delivra-celecoxib creams and may
offer significant advantages over oral medication. These
formulations will provide better localization of the drug at the
site of need, yielding quicker and longer lasting relief.
"This impressive data further validates Delivra's platform
technology by outperforming oral delivery and offering patients an
effective, safe and convenient cream for pain management. Our
robust pharmaceutical pipeline of high-value innovative products,
including Delivra-ibuprofen and Delivra-celecoxib formulations,
provide an array of unique commercialization opportunities. As
such, we will continue to pursue out-licensing opportunities for
major global markets to unlock the value of our portfolio," said
Dr. Joseph Gabriele, CEO of
Delivra.
For these two formulations, the Company has two PCT patent
pending applications.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin, in a
targeted manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivRelief™ brand, for conditions
such as joint and muscle pain, nerve pain, varicose veins, wound
healing, and sports performance. LivRelief™ products are
available in over 6,000 retail locations, including pharmacies,
grocery chains, and independent health food stores across
Canada, including, but not limited
to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London
Drugs, and on-line at www.livrelief.com. In parallel with its
consumer products business, Delivra also has a mandate to license
its patent-pending, proprietary transdermal delivery technology
platform to pharmaceutical companies globally, for the repurposing
of pharmaceutical molecules transdermally to treat a broad range of
conditions, along with licensing its over-the-counter products
globally. Delivra is headquartered in Hamilton, Ontario and has a research and
development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at
www.delivracorp.com and www.livrelief.com.
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's revenues and financial
performance; the Company's drug research and development plans; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Delivra to differ materially from those
anticipated or implied in such forward-looking statements. The
Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no
assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein,
management has assumed that business and economic conditions
affecting Delivra will continue substantially in the ordinary
course and will be favourable to Delivra; that the Company will
continue to complete orders with existing customers and control
product pricing and expenses that clinical testing results will
justify commercialization of the Company's drug candidates; that
Delivra will be able to obtain all requisite regulatory approvals
to commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include: the
ability of the Company to maintain existing product sales with
current customers at existing product pricing and expenses;
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the ability of the Company to generate sales and
profits; the Company's ability to raise additional capital if and
when necessary; intellectual property disputes; increased
competition from pharmaceutical and biotechnology companies;
changes in equity markets, inflation, and changes in exchange
rates; and other factors as described in detail in Delivra's public
filings, all of which may be viewed on SEDAR (www.sedar.com). Given
these risks and uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
Except as required by law, Delivra disclaims any intention and
assumes no obligation to update or revise any forward-looking
statements to reflect actual results, whether as a result of new
information, future events, changes in assumptions, changes in
factors affecting such forward-looking statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp